|

Ublituximab Clinical Trials

5 actively recruiting trials across 4 locations

Also known as: BRIUMVI, Briumvi, TG-1101

Pipeline

Early 1: 1Phase 3: 2Phase 4: 1

Top Sponsors

  • TG Therapeutics, Inc.2
  • Northwestern University1
  • Neurology Center of New England P.C.1
  • Georgia State University1

Indications

  • Multiple Sclerosis5
  • Relapsing Multiple Sclerosis2
  • Multiple Sclerosis (MS) - Relapsing-remitting2
  • Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis1

Other1 trial

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Phase 3

Birmingham, Alabama1 trial

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

TG Therapeutics Investigational Trial Site

Phase 3

Atlanta, Georgia1 trial

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

Georgia State University

Early 1

Chicago, Illinois1 trial

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Northwestern Memorial Hospital

Phase 4

Foxborough, Massachusetts1 trial

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

Neurology Center of New England P.C.

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.